Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03237000 |
Recruitment Status : Unknown
Verified July 2017 by Ahmed Maged, Cairo University.
Recruitment status was: Not yet recruiting
First Posted : August 2, 2017
Last Update Posted : August 2, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Admission CTG for 20 minutes Settings on a CTG machine was standardised to enable a consistent approach of interpretation of traces. Paper speed of 3cm per minute will be adopted. Maternal heart rate was recorded and noted on CTG. Following birth date, time and mode of delivery will be labelled on CTG.
Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
- Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.
- Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.
Another 20 minutes CTG strip will be performed 20 minutes after administration of IV loading MgSO4, 7H2O and thus ensuring that MgSO4 has reached peak serum levels
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Preeclampsia | Drug: MgSO4 | Phase 4 |
Admission CTG:
Admission CTG will be performed for 20 minutes
I-Settings:
- Settings on a CTG machine will be standardised to enable a consistent approach of interpretation of traces.
- Paper speed of 3cm per minute will be adopted.
- CTGs will be labelled with mother's name, hospital number.
- Date and time settings on machines will be labelled at commencement of tracing.
- Maternal heart rate will be recorded and noted on CTG.
- Following birth date, time and mode of delivery will be labelled on CTG.
Magnesium Sulphate hepatahydrate administration:
Magnesium sulphate will be administered by continuous intravenous infusion according to our hospital protocol as follows:
- Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.
- Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.
-
Magnesium toxicity was monitored by hourly assessment of:
- Patellar reflexes should be present.
- Respiratory rate not < 16/min.
- Urine output not < 100ml / hr. Another 20 minutes CTG strip will be performed 20 minutes after administration of IV loading MgSO4, 7H2O and thus ensuring that MgSO4 has reached peak serum levels
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
|
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy |
Estimated Study Start Date : | August 1, 2017 |
Estimated Primary Completion Date : | December 2017 |
Estimated Study Completion Date : | January 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: MgSO4
Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
|
Drug: MgSO4
Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
Other Name: Magnisium sulfate |
- Fetal heart rate tracing [ Time Frame: 20 minutes after MgSO4 administration ]Settings on a CTG machine is standardised to enable a consistent approach of interpretation of traces. Paper speed of 3cm per minute is adopted

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pregnant Women in the third trimester.
- Severely preeclamptic patients.
- Singleton Pregnancy.
- Patients with normal admission CTG
Exclusion Criteria:
- Evidence of fetal anomalies on scan.
- Concomitant maternal morbidities as diabetes, cardiac disease.
- Patients contraindicated to take MgSo4 e.g.: advanced renal disease.
- Abnormal admission CTG.
- Morbid obesity.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03237000
Contact: Ahmed Maged, MD | 01005227404 | prof.ahmedmaged@gmail.com | |
Contact: Ahmed Ibrahim, MD | gyndoctor77@gmail.com |
Egypt | |
Kasr Alainy medical school | |
Cairo, Egypt, 12151 |
Principal Investigator: | Ahmed Maged, MD | kasr Alainy medical school |
Responsible Party: | Ahmed Maged, Professor, Cairo University |
ClinicalTrials.gov Identifier: | NCT03237000 |
Other Study ID Numbers: |
7 |
First Posted: | August 2, 2017 Key Record Dates |
Last Update Posted: | August 2, 2017 |
Last Verified: | July 2017 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Preeclampsia MgSO4 |
Pre-Eclampsia Hypertension, Pregnancy-Induced Pregnancy Complications |